CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients

被引：0
|
作者：
M. V. Lima
G. S. Ribeiro
E. T. Mesquita
P. R. Victer
R. Vianna-Jorge
机构：
[1] Hospital Universitário Antônio Pedro,Departamento de Medicina Clínica
[2] Universidade Federal Fluminense,Departamento de Patologia
[3] Hospital Universitário Antônio Pedro,Departamento de Farmacologia Básica e Clínica
[4] Universidade Federal Fluminense,Coordenação de Pesquisa
[5] Universidade Federal do Rio de Janeiro,undefined
[6] Cidade Universitária,undefined
[7] Centro de Ciências da Saúde,undefined
[8] Instituto Nacional de Câncer,undefined
来源：
European Journal of Clinical Pharmacology | 2008年 / 64卷
关键词：
Gene polymorphism; Brazilians; Warfarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 15
页数：6
相关论文
共 50 条
  • [41] First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele
    O'Brien, Travis J.
    Kidd, Robert S.
    Richard, Craig A. H.
    Ha, Ngoc-Han
    Witcher, Preston
    Tran, Linda V.
    Barbour, April
    Tuck, Matthew
    McIntosh, Samantha D.
    Douglas, Jacqueline N.
    Harralson, Arthur F.
    CLINICA CHIMICA ACTA, 2013, 424 : 73 - 75
  • [42] A haplotype of CYP2C9 associated with warfarin sensitivity in mechanical heart valve replacement patients
    Lee, Su-Jun
    Jang, Yin Jin
    Cha, Eun-Young
    Kim, Ho-Sook
    Lee, Sang Seop
    Shin, Jae-Gook
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (02) : 213 - 221
  • [43] CYP2C9 polymorphisms: Considerations in NSAID therapy
    Ali, Zaynah K.
    Kim, Rebekah J.
    Ysla, Francis M.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (01) : 108 - 114
  • [44] PREVALENCE OF COMBINATORIAL CYP2C9 AND VKORC1 GENOTYPES IN PUERTO RICANS: IMPLICATIONS FOR WARFARIN MANAGEMENT IN HISPANICS
    Duconge, Jorge
    Cadilla, Carmen L.
    Windemuth, Andreas
    Kocherla, Mohan
    Gorowski, Krystyna
    Seip, Richard L.
    Bogaard, Kali
    Renta, Jessica Y.
    Piovanetti, Paola
    D'Agostino, Darrin
    Santiago-Borrero, Pedro J.
    Ruano, Gualberto
    ETHNICITY & DISEASE, 2009, 19 (04) : 390 - 395
  • [45] Prediction of the impact of CYP2C9 and VKORC1 genotypes on warfarin-sorafenib interactions in whites and Asians
    Asari, Kazuhiko
    Takahashi, Harumi
    PHARMACOGENOMICS, 2020, 21 (12) : 853 - 862
  • [46] Influence of CYP2C9 Polymorphisms on Plasma Concentration of Warfarin and 7-Hydroxy Warfarin in South Indian Patients
    Kumar, Dhakchinamoorthi Krishna
    Uppugunduri, Chakradhara Rao Satyanarayana
    Shewade, Deepak Gopal
    Chandran, Sai B., V
    Adithan, Chandrasekaran
    CURRENT DRUG METABOLISM, 2021, 22 (12) : 989 - 995
  • [47] Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans
    Limdi, Nita A.
    KArnett, Donna
    Goldstein, Joyce A.
    Beasley, T. Mark
    McGwin, Gerald
    Adler, Brian K.
    Acton, Ronald T.
    PHARMACOGENOMICS, 2008, 9 (05) : 511 - 526
  • [48] Testing for CYP2C9 Before Anticoagulant Therapy
    Mark H. Eckman
    Steven M. Greenberg
    Jonathan Rosand
    Journal of General Internal Medicine, 2009, 24 : 993 - 993
  • [49] CYP2C9 Genotype-DependentWarfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R-and S-Warfarin and Their Oxidative Metabolites
    Flora, Darcy R.
    Rettie, Allan E.
    Brundage, Richard C.
    Tracy, Timothy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (03) : 382 - 393
  • [50] Current pharmacogenetic developments in oral anticoagulation therapy:: The influence of variant VKORCI and CYP2C9 alleles
    Oldenburg, Johannes
    Bevans, Carville G.
    Fregin, Andreas
    Geisen, Christof
    Mueller-Reible, Clemens
    Watzka, Matthias
    THROMBOSIS AND HAEMOSTASIS, 2007, 98 (03) : 570 - 578
12345